PVantage™ Safety Data Automation
Pharmacovigilance Adverse Event Management Platform
PVantage is a modular offering, able to scale with your program as case volume increases.
PVantage™ is an innovative platform, that allows drug safety teams to streamline and automate case processing activities to ensure accuracy, efficiency, and compliance. This tool works with clinical trial and post market safety data and provides the ability to integrate, analyze, and visualize patient, program, and drug class information for greater control and oversight of your safety data.
PVantage is a proprietary cloud-based solution that allows Sponsors to elect the degree of automation of all workflows for case intake, case processing, safety data analysis and generation of standard reports. A dedicated, virtual managed environment provides Sponsors with a consistently updated platform and assures compliance with ever-changing global pharmacovigilance regulations.
Click to learn more about Comprehensive Safety Solutions to accompany this technology.
Allows for the automation and streamlining of case intake, including autopopulation of case data from a variety of sources
This module enables efficient and seamless data exchange between the Clinical electronic data capture (EDC) system and the Safety database, resulting in time reduction for case processing and data reconciliation while providing increases in quality.
PVantage dashboards allow for the visualization of complex safety data, making it easier to understand and interpret the data using a wide range of visualization options. The customizable data visualization layer allows for near real-time data inquiry and more informed decisions. In addition, sponsors can customize reporting content and cadence, including status reports, cumulative safety listings, KPIs, and other compliance reports.
With PVantage, Sponsors gain an accelerated technological advantage with greater visualization and efficient reporting of safety data.
Suggested For You
webinar
September 26th, 2024
Regulatory Pathways for Nonprescription Drugs: A Deep Dive into OTC Monograph Reform and FDA Guidance
regulatory intelligence
August 27th, 2024
Recent Guidance on Diversity Action Planning
regulatory intelligence
August 26th, 2024
Oncology Programs at the FDA
regulatory intelligence
August 26th, 2024
Three Key Take Reflections on the Recent Donanemab Approval
webinar
September 12th, 2024
No Stone Unturned: Optimizing the Use of Expedited Pathways and Oncology Center of Excellence Programs to Optimize Drug Development in Oncology
regulatory intelligence
August 9th, 2024
FDA Updates 2024 Language Access Plan
regulatory intelligence
August 3rd, 2024
EMA Launches New Pilot Program for Orphan Medical Devices
perspectives
July 30th, 2024
The Critical Role of Quality Control (QC) – Medical Writing and Beyond
regulatory intelligence
July 26th, 2024
Key Decision Points for Recent Oncology Approvals
regulatory intelligence
July 24th, 2024
Comments Open for Postapproval Manufacturing Changes to Biosimilar and Interchangeable Biosimilar Products
perspectives
July 23rd, 2024
PSI 2024 Ignited Conversations on External Data Sources, Requirements for Estimands, and Bayesian Methodology for Statisticians in Pharma
news
July 17th, 2024
Industry Veteran Ben Dudley Joins MMS as Chief Commercial Officer (CCO) to Drive Continued Growth for the Data-focused Clinical Research Organization